Effect of Empagliflozin versus Dapagliflozin on calcium-phosphate metabolism.
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/01/049154
- Lead Sponsor
- All India Institute Of Medical Sciences, Patna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Previously diagnosed type 2 Diabetes Mellitus patient already on Metformin
(1000mg/day) >=3 month with FBS >=130 mg/dl or PPBS >=180mg/dl or HbA1C >=7%
2. Age: >=18years and <=55 years
3. Gender: Both
1.Patient already on diabetic treatment on drugs other than Metformin.
2.Patient with Renal disease (S. Creatinine >=1.2mg/dl) Liver disease (ALT/AST >50IU)
3.Pregnant and lactating women
4.Patients unwilling/unable to give consent
5.Patient on drugs which may cause hyperglycaemia like (Steroids, Beta2 agonist, Thiazides, Antipsychotics) .
6.Patient on drugs causing hypoglycaemia (Beta blocker, Fluoroquinolones, Pentamidine).
7. Patient on drugs causing derangement of vitamin D, PTH level (Phenytoin, phenobarbital, warfarin, Cyclophosphamide, Tamoxifen, Rifampicin, Antiviral drugs).
8. Patient on vitamin D medication and calcium medication.
9. Patient on drugs which derange calcium metabolism (Thiazides, Loop diuretics).
10. Patient with vitamin D level less than 20 ng/ml.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of Empagliflozin versus Dapagliflozin on circulating markers of calcium-phosphate metabolismTimepoint: 0 month, 3 month
- Secondary Outcome Measures
Name Time Method i) Efficacy of Empagliflozin versus Dapagliflozin on blood glucose parameters. <br/ ><br> ii) Adverse drug reaction profile (ADR Profile) in patients receiving Empagliflozin versus Dapagliflozin. <br/ ><br>Timepoint: 0 month, 1 month, 2 month, 3 month